4D Molecular Therapeutics Inc
$ 8.84
1.32%
11 Jun - close price
- Market Cap 482,510,000 USD
- Current Price $ 8.84
- High / Low $ 8.88 / 8.37
- Stock P/E N/A
- Book Value 8.64
- EPS -2.57
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -0.35 %
- 52 Week High 12.34
- 52 Week Low 3.68
About
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors. The company is headquartered in Emeryville, California.
Analyst Target Price
$28.22
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-18 | 2025-11-10 | 2025-08-11 | 2025-05-08 | 2025-02-28 | 2024-11-13 | 2024-08-08 | 2024-05-09 | 2024-02-29 | 2023-11-09 | 2023-08-09 |
| Reported EPS | -1.01 | 0.43 | -1.01 | -0.98 | -0.86 | -0.9 | -0.79 | -0.63 | -0.66 | -0.75 | -0.24 | -0.77 |
| Estimated EPS | -0.875 | -0.532 | -1.01 | -0.73 | -0.8621 | -0.8379 | -0.7 | -0.7 | -0.74 | -0.74 | -0.59 | -0.81 |
| Surprise | -0.135 | 0.962 | 0 | -0.25 | 0.0021 | -0.0621 | -0.09 | 0.07 | 0.08 | -0.01 | 0.35 | 0.04 |
| Surprise Percentage | -15.4286% | 180.8271% | 0% | -34.2466% | 0.2436% | -7.4114% | -12.8571% | 10% | 10.8108% | -1.3514% | 59.322% | 4.9383% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FDMT
2026-06-11 03:09:30
The Fabry Disease market is projected to reach approximately USD 1,700 million in 2024 and is expected to grow significantly by 2034, driven by increasing prevalence and emerging therapies. Key players like Sangamo Therapeutics are advancing gene therapies such as ST-920, with potential accelerated FDA approval. The United States holds the largest market share and diagnosed patient population, with Germany leading in Europe.
2026-06-03 21:10:06
4D-150, a gene therapy developed by 4D Molecular Therapeutics, Inc. (FDMT), aims to treat wet AMD and diabetic eye disease by providing sustained anti-VEGF expression. This approach is intended to reduce the burden of frequent injections and improve patient outcomes. Phase II data indicates strong efficacy and safety, with Phase III results anticipated next year, positioning the product for significant market impact and integration into current medical practice.
2026-06-03 01:09:13
David Kirn, CEO of 4D Molecular Therapeutics, sold 1,922 shares of company stock for approximately $19,257. This sale was conducted under a pre-arranged 10b5-1 trading plan. The company's stock has seen a 159% return over the past year, and Kirn retains over one million shares.
2026-06-02 21:08:59
David Kirn, a director and officer at 4D Molecular Therapeutics (NASDAQ: FDMT), sold 1,922 shares of common stock at a weighted average price of $10.0197 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on January 9, 2026. Following this sale, Kirn still holds a substantial position of 1,057,231 shares in the company.
2026-06-02 21:08:59
David Kirn, CEO of 4D Molecular Therapeutics, sold 1,922 shares for approximately $19,257, following a 159% stock return over the past year. The sale was part of a pre-arranged trading plan. The company is advancing with its pivotal study for wet age-related macular degeneration, while analyst price targets show mixed opinions, with RBC increasing its target and Jefferies lowering its target.
2026-06-01 22:10:00
4D Molecular Therapeutics, Inc. (FDMT) has filed a Form 144 Notice of Proposed Sale of Securities, indicating the intention to sell 1922 shares of Class A Common Stock with an aggregate market value of $18662.62. The shares were acquired from the issuer in a private transaction on December 15, 2020. Goldman Sachs & Co. LLC is listed as the broker for the proposed sale.
